Switch theme
Sign up to access all valuation multiples
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
1900
114K+
LTM Revenue $42.3B
LTM EBITDA $10.9B
$241B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abbott Laboratories has a last 12-month revenue of $42.3B and a last 12-month EBITDA of $10.9B.
In the most recent fiscal year, Abbott Laboratories achieved revenue of $40.1B and an EBITDA of $10.5B.
Abbott Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abbott Laboratories valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.3B | XXX |
| Gross Profit | $24.5B | $24.5B | $22.1B | XXX | XXX |
| Gross Margin | 57% | 56% | 55% | XXX | XXX |
| EBITDA | $12.3B | $12.1B | $10.5B | $10.9B | XXX |
| EBITDA Margin | 29% | 28% | 26% | 26% | XXX |
| Net Profit | $7.1B | $6.9B | $5.7B | XXX | XXX |
| Net Margin | 16% | 16% | 14% | XXX | XXX |
| Net Debt | $8.3B | $6.9B | $7.8B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Abbott Laboratories's stock price is $135.
Abbott Laboratories has current market cap of $234B, and EV of $241B.
See Abbott Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $241B | $234B | XXX | XXX | XXX | XXX | $4.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Abbott Laboratories has market cap of $234B and EV of $241B.
Abbott Laboratories's trades at 5.7x LTM EV/Revenue multiple, and 22.1x LTM EBITDA.
Analysts estimate Abbott Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Abbott Laboratories and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $241B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | XXX | XXX |
| EV/EBITDA | 22.9x | XXX | XXX | XXX |
| P/E | 40.9x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 47.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAbbott Laboratories's NTM/LTM revenue growth is 6%
Abbott Laboratories's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Abbott Laboratories's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Abbott Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Abbott Laboratories and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Electromed | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abbott Laboratories acquired XXX companies to date.
Last acquisition by Abbott Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Abbott Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Abbott Laboratories founded? | Abbott Laboratories was founded in 1900. |
| Where is Abbott Laboratories headquartered? | Abbott Laboratories is headquartered in United States of America. |
| How many employees does Abbott Laboratories have? | As of today, Abbott Laboratories has 114K+ employees. |
| Who is the CEO of Abbott Laboratories? | Abbott Laboratories's CEO is Mr. Robert B. Ford. |
| Is Abbott Laboratories publicy listed? | Yes, Abbott Laboratories is a public company listed on NYS. |
| What is the stock symbol of Abbott Laboratories? | Abbott Laboratories trades under ABT ticker. |
| When did Abbott Laboratories go public? | Abbott Laboratories went public in 1949. |
| Who are competitors of Abbott Laboratories? | Similar companies to Abbott Laboratories include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem. |
| What is the current market cap of Abbott Laboratories? | Abbott Laboratories's current market cap is $234B |
| What is the current revenue of Abbott Laboratories? | Abbott Laboratories's last 12-month revenue is $42.3B. |
| What is the current EBITDA of Abbott Laboratories? | Abbott Laboratories's last 12-month EBITDA is $10.9B. |
| What is the current EV/Revenue multiple of Abbott Laboratories? | Current revenue multiple of Abbott Laboratories is 5.7x. |
| What is the current EV/EBITDA multiple of Abbott Laboratories? | Current EBITDA multiple of Abbott Laboratories is 22.1x. |
| What is the current revenue growth of Abbott Laboratories? | Abbott Laboratories revenue growth between 2023 and 2024 was -8%. |
| Is Abbott Laboratories profitable? | Yes, Abbott Laboratories is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
